Appointment of Managing Director and CEO
NZX Code: ATM
ASX Code: A2M
The a2 Milk Company Limited
www.thea2milkcompany.com
11 August 2020
NZX/ASX Market Release
Appointment of Managing Director and CEO
The Board of Directors of The a2 Milk Company Limited is pleased to announce the appointment of David
Bortolussi to the role of Managing Director and CEO based in Sydney. David is expected to commence in the
role early in the 2021 calendar year. David will succeed Geoffrey Babidge who has been in the CEO role on
an interim basis since December 2019.
David has many strengths that make him well suited to leading the company at this stage of its growth,
including extensive international leadership experience in the consumer and retail sector, particularly in
corporate strategy and business transformation with a focus on brand development and innovation, multi-
channel management and supply chain operations.
David joins the company from his most recent role as Group President - International Innerwear,
HanesBrands. He joined Pacific Brands in 2009 initially as Chief Financial & Operating Officer taking over as
CEO in 2014, during which he restructured and transformed the business into a brand focused, leading
omni-channel retailer with successful wholesale partnerships, delivering double digit compound annual
growth in sales and earnings over the past five years. In 2016, HanesBrands acquired Pacific Brands and
expanded David’s role to cover Australasia and subsequently its international innerwear operations outside
of the Americas. Over this period, David has been responsible for and had extensive exposure to Pacific
Brands and Hanesbrands’ Asian sourcing markets, particularly China including various brand distribution
partnerships in the region.
Prior to this David spent five years at Foster’s Group, where he held the role of Chief Strategy Officer
responsible for corporate strategy, M&A, business development and performance improvement. In this
role, David was instrumental in leading the process that ultimately led to the operational separation and
demerger of the domestic beer and global wine businesses, generating significant shareholder value. Prior
to Foster’s Group, David held senior consulting roles at McKinsey & Company and PwC.
Chairman of The a2 Milk Company, David Hearn, said: “Following an extensive global search, the Board is
delighted to have secured David for this role. David has demonstrated significant skill in guiding businesses
through periods of significant growth whilst also effectively managing the changes that expansion
frequently requires.”
2
“The a2 Milk Company is going through a period of continued strong growth in dynamic markets and
David’s skillset and comprehensive strategic and operational experience will serve the company well. I am
looking forward to working with David as we navigate these challenges together with the board and
management team.”
“As Managing Director and CEO, David will assume leadership of the Company’s Executive Leadership
Team, which has a strong and diverse skill set and deep experience of the business across all key markets in
which the company operates,” said Mr Hearn.
David Bortolussi said: “I have always admired The a2 Milk Company’s achievements and I am looking
forward to joining the board and management team to continue the development of such an extraordinary
business. The team at a2 has created a very distinctive consumer proposition, amazing brand and strong
culture with so much potential. I’m thrilled to have the opportunity to lead such a talented and experienced
team, and to be part of the next phase of growth”.
The Board also wishes to express its sincere thanks to Geoff for stepping back into the business in
December last year and so capably leading the company over the past eight months.
As noted above, it is expected that David Bortolussi will commence his role early in the 2021 calendar year,
given that he has a 6 month notice period with his current employer, although the exact timing will be
agreed nearer the date. Geoff will continue to lead the company until then, and he will work closely with
David Bortolussi and the Board on an onboarding plan to ensure that the current momentum of the
business continues.
The material terms of David’s employment agreement are summarised in the Appendix.
David Hearn
Chairman
The a2 Milk Company Limited
For further information, please contact:
Investors / Analysts
David Akers
Head of Investor Relations
M +61 412 944 577
david.akers@a2milk.com
Media
Rick Willis
Media partner
M +61 411 839 344
rick@networkfour.com.au
3
Summary of Material Terms of the Executive Service Agreement for David Bortolussi
Material Term Summary
Commencement Date: Expected to be early 2021 calendar year (date to be confirmed subject to
existing employment commitments).
Term: Ongoing (no fixed term).
Total Fixed Remuneration: AUD 1,750,000 per annum (inclusive of superannuation), to be reviewed
annually.
Relocation Allowance: An allowance will be paid to assist David with his relocation from Melbourne to
Sydney.
Short Term Incentive (STI): On an annual basis, David will be entitled to participate in the Company’s STI
plan. For the 2020/21 financial year, David may receive an STI payment of a
target of 120% of his Total Fixed Remuneration based on the achievement of
performance objectives to be determined by the Board. As for all senior
executives, the STI payment is subject to adjustment by an individual multiplier
of between 0% and 130% based on the Board’s assessment of David’s individual
performance.
Long Term Incentive (LTI): On an annual basis, David will be invited to take up performance rights under
the Company’s LTI plan. For the 2020/21 financial year, David will be offered
performance rights equivalent to 150% of his Total Fixed Remuneration with
vesting assessed over a three-year period based on performance hurdles and
vesting conditions to be determined by the Board.
Transition Benefits: On a one-off basis, David will receive the following transition benefits as partial
compensation for vested and unvested STI, LTI and other entitlements that he
will forfeit on resigning from his current employment:
• AUD 1,270,000 cash payment on commencement date; and
• AUD 3,700,000 of rights to acquire ordinary shares calculated by
reference to the 90-day VWAP over the period that ends five ASX
trading days before the commencement date, with 50% vesting on the
first anniversary of the commencement date and the remaining 50%
vesting on the second anniversary of the commencement date. These
rights will not be subject to performance hurdles but are otherwise
issued on terms similar to performance rights.
Other than to meet any tax obligations, no shares held by David can be sold until
David holds sufficient shares to meet the company’s minimum shareholding
requirement.
The transition benefits equate to approximately 80% of the total potential
entitlements that David will forfeit, the majority of which are not at risk and
subject to time-based vesting only.
Notice Period: Generally, resignation by David requires six months’ notice and termination
(other than for cause) by the Company requires twelve months’ notice.
Leave: Five weeks per annum paid annual leave
Other Terms: The agreement also includes standard terms covering expense reimbursement,
conflicts of interest, confidentiality, intellectual property and moral rights,
clawbacks and restraints upon termination (which address non-competition, as
well as non-solicitation of employees, customers and suppliers).
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: AFT appoints Anita Baldauf as a director2020-11-03
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com Market and media release 4th November 2020 AFT appoints Anita Baldauf as a d…”
- AOF — AoFrio Limited: Wellington Drive Technologies announces CEO stepping down2020-10-29
“® is a registered Trademark of Wellington Drive Technologies WT 9463 Wellington Drive Technologies Ltd P: +64 9 477 4500 E: info@wdtl.com 21 Arrenway Drive, Rosedale, Auckland 0632 PO Box 302-533 North Harbour, Auckland 0751,…”
- AFT — AFT Pharmaceuticals Limited: AFT FY2020 Results annoucement2020-05-19
“/ David Flacks/ Dr Hartley Atkinson/ Marree Atkinson/ Nathan (Nate) Hukill/ Jon Lamb INDEPENDENT DIRECTOR Appointed 4 September 2012 / Dr James (Jim) Burns IINDEPENDENT DIRECTOR Appointed 17 September 2015 / Dr John Douglas (Doug) Wilson INDEPENDENT DIRECTOR Appointed 4 September…”